Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

Non-Malignant Blood Disorders

Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study

Br J Haematol

Lucchini E, Vianelli N, Consoli U, Carli G, Carrai V, Carpenedo M, De Stefano V, Gaidano G, Palandri F, Auteri G, Rossi E, Patriarca A, Innao V, Marchesini G, Ballerini M, Rossetti MC, Mosini G, Sciancalepore P, Agnelli Giacchello J, Musto P, Rivolti E, Soverini G, Borchiellini A, Clissa C, Pane F, Galimberti S, Pavone V, Poloni A, Buccisano F, Musso M, Fazi P, Paoloni F, Gorreo Renzulli L, Zaja F

doi: 10.1111/bjh.70069

Non-Malignant Blood Disorders

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience

Am J Hematol

Fattizzo B, Sambruna E, Miyakawa Y, Michel M, Visco C, Fillitz M, Kannourakis G, Greve MB, Kleemiss M, Cid J, Patriarca A, Pavan L, Dizdari A, Maschio N, Sau A, Bitetti C, Colombo RM, Curreli L, Lame D, Markovic U, Pappagallo F, Pedone GL, Rapezzi D, Sammartano V, Tumedei N, Solimando AG, Marit J, Fianchi L, Khwaja J, De Vivo A, Lanza F, Vianello F, Oliva EN, Broome C, Passamonti F, Jaeger U, Jilma B, Moulis G, Barcellini W

doi: 10.1002/ajh.70307

Leukemia

Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study

Br J Haematol

Costa A, Scalzulli E, Carmosino I, Bisegna ML, Laganà A, Ielo C, Cappelli L, Martelli M, Breccia M

doi: 10.1111/bjh.70418

Leukemia

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial

Lancet

Davids MS, Eyre TA, Woyach JA, Roeker LE, Ferrajoli A, Wang Y, Tam CS, Jurczak W, Zinzani PL, Šimkovič M, Li JY, Bosch F, Roos-Weil D, Cramer P, Osterborg A, Islam P, Jacobs R, Skarbnik A, Bhat SA, Kang S, Chen M, Nguyen B, McNeely SC, Chung KL, Oliveira JM, Ito R, Ghia P, Wierda WG

doi: 10.1016/S0140-6736(26)01204-3

Non-Malignant Blood Disorders

Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry

Am J Hematol

Röth A, Patriquin CJ, Szer J, Terriou L, Patel AS, Metzger J, Gustovic P, Nishimura JI, Brodsky RA

doi: 10.1002/ajh.70268

Skin Cancer

Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study

Int J Cancer

Gutzmer R, Weichenthal M, Eigentler T, Mohr P, Sickmann T, Dücker P, Gebhardt C, Haferkamp S, Kähler KC, Meier F, Pföhler C, Sindrilaru A, Terheyden P, von Wasielewski I, Ugurel S, Ulrich J, Utikal J, Weishaupt C, Schadendorf D

doi: 10.1002/ijc.70440

Sarcoma

Trabectedin in the treatment of soft tissue sarcoma: Real-world data on effectiveness, safety, and financial implications from a European comprehensive cancer center

Int J Cancer

Giraud JS, Watson S, Acramel A, Laurence V, Tzanis D, Bonvalot S, El Zein S, Nicolas N, Cros C, Desmaris R, Bonnet C

doi: 10.1002/ijc.70403

Lymphoma

Effects of chronic lymphocytic leukaemia (CLL)-directed therapy on diffuse large B-cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort

Br J Haematol

Katsimigas A, Werling M, Frederiksen CM, Vainer N, Rostgaard K, Ben-Dali Y, Hleuhel MH, Brieghel C, Niemann CU, da Cunha-Bang C

doi: 10.1111/bjh.70651

Leukemia

Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009-2019: A Real-World Study From the UK's Haematological Malignancy Research Network

Int J Cancer

Kane E, Smith A, Howell D, Cargo C, Rothwell K, Green S, Patmore R, Roman E

doi: 10.1002/ijc.70518

Related content

Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience

Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial

Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry

Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study

Trabectedin in the treatment of soft tissue sarcoma: Real-world data on effectiveness, safety, and financial implications from a European comprehensive cancer center

Effects of chronic lymphocytic leukaemia (CLL)-directed therapy on diffuse large B-cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort

Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009-2019: A Real-World Study From the UK's Haematological Malignancy Research Network